Trial register facet
Trial records for Mazdutide
18 records for Mazdutide, of which 5 are published trials.
Showing 0 records on this page
Records
18 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| GLORY-1 | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 610 | 2025 | Moderate |
| GLORY-1-QOLprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| GLORY-1-REGIONAL-CNprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| GLORY-1-REGIONAL-JPprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2025 | Very low |
| GLORY-1-OLEprogramme record | Mazdutide | Phase 3 | Reported | Single-arm open-label | — | 2025 | Very low |
| DREAMS-1 | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 319 | 2024 | Moderate |
| DREAMS-2 | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 731 | 2024 | Moderate |
| DREAMS-2-RENAL-IMPprogramme record | Mazdutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| DREAMS-2-PKprogramme record | Mazdutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| MAZ-PH2-OBESITY | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 248 | 2023 | Moderate |
| MAZ-PH2-OBESITY-REGIONAL-JPprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-BODY-COMPprogramme record | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-QOLprogramme record | Mazdutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| MAZ-PH2-OBESITY-REGIONAL-CNprogramme record | Mazdutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DREAMS-3 | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, active-controlled | — | — | Not rated |
| DREAMS-3-BODY-COMPprogramme record | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| DREAMS-3-REGIONAL-JPprogramme record | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| DREAMS-3-REGIONAL-CNprogramme record | Mazdutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |